Biogen turns to R&D vet as Ehlers exits

While Biogen head of R&D Michael Ehlers is departing the biotech to join the VC ranks amid a series of recent clinical disappointments, pipeline additions during his tenure could start to bear fruit over the next nine months.

Biogen Inc. (NASDAQ:BIIB) said Al Sandrock, who has been at the company since 1998 and CMO since 2012, will take on Ehlers’ responsibilities while maintaining his current post. ...